0.0164USD-18.00%Mkt Cap: —P/E: —Last update: 2026-06-01
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product th…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)34.55K USD
Gross Profit-116 USD
Net Income (TTM)-24.48M USD
Revenue/Share0.4260 USD
Last Price0.0164 USD
Fiscal Year End—
MR Quarter—
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.00
EPS (TTM)—
EPS (Forward)—
52W Range
0.01490% of range0.6000
52W High0.6000 USD
52W Low0.0149 USD
Profitability
Gross Margin-1.87%
Oper. Margin-5805.98%
EBITDA Margin0.00%
Profit Margin-394725.06%
ROE383.93%
ROA-1865.68%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.92M USD
CapEx (TTM)—
FCF Margin63450.70%
FCF Yield—
Net Debt-4.36M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.81
Current Ratio2.26
Quick Ratio1.86
Book Value/Sh23.10 USD
Cash/Share4.522 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:30
Split DateMay 11, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float1.20M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)365
Avg Vol (10d)—
Technical Indicators
RSI (14)47.5
MACD-0.0184
MACD Signal-0.0099
MACD Hist.-0.0085
BB Upper0.4348 USD
BB Middle0.0773 USD
BB Lower-0.2802 USD
BB Width924.43%
ATR (14)0.0539 USD
Vol Ratio (20d)0.00x